No secondary treatment failure with Xeomin©

被引：0

作者：

Jost, W. ^{[1
]}

机构：

[1] Deutsch Klin Diagnost, D-6200 Wiesbaden, Germany

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2009年 / 285卷

关键词：

D O I：

10.1016/S0022-510X(09)71129-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S297 / S297

页数：1

共 50 条

[41] TREATMENT OF DIABETIC PATIENTS WITH CHLORPROPAMID AFTER SECONDARY FAILURE ON TOLBUTAMIDE
TITTLE, CR
KERR, JH
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1965, 7 (05): : 297 - &
[42] Do Botox and Xeomin Differ with Respect to Tolerability and Effectiveness in Treatment of Chronic Migraine?
Lucchese, S.
HEADACHE, 2018, 58 : 101 - 101
[43] CLINICAL AND URODYNAMIC EFFICACY OF XEOMIN IN THE TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY: PRELIMINARY RESULTS
Silvia, Proietti
Silvia, Giovannozzi
Emanuele, Lepri
Luca, Lepri
Marilena, Gubbiotti
Antonella, Giannantoni
NEUROUROLOGY AND URODYNAMICS, 2011, 30 : 45 - 46
[44] Equivalent potency of Xeomin® and Botox®
Dressler, D.
Mander, G. J.
Fink, K.
MOVEMENT DISORDERS, 2008, 23 (01) : S20 - S21
[45] FDA Approves Xeomin (incobotulinumtoxinA)
不详
JOURNAL OF DRUGS IN DERMATOLOGY, 2011, 10 (09) : 1076 - 1076
[46] Equivalent potency of Xeomin® and BOTOX®
Dressler, Dirk
Mander, Gerd J.
Fink, Klaus
TOXICON, 2008, 51 : 10 - 10
[47] Secondary treatment failure in a patient with cervical dystonia after repetitive treatment with incobotulinumtoxinA and abobotulinumtoxinA
Jochim, A.
Castrop, F.
Jochim, B.
Haslinger, B.
MOVEMENT DISORDERS, 2014, 29 : S506 - S506
[48] No difference in efficacy between Xeomin® and Botox® in the treatment of cervical dystonia -: a detailed subgroup analysis
Hefter, H.
Benecke, R.
Comes, G.
Grafe, S.
MOVEMENT DISORDERS, 2007, 22 : S120 - S120
[49] IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®)
Dirk Dressler
Fereshte Adib Saberi
Hans Bigalke
Journal of Neural Transmission, 2014, 121 : 769 - 771
[50] The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
Morgante, Francesca
Bavikatte, Ganesh
Anwar, Fahim
Mohamed, Biju
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2019, 12

← 1 2 3 4 5 →